Absolute risk and risk factors for stroke mortality in patients with end-stage kidney disease (ESKD): population-based cohort study using data linkage

Nicolette De La Mata, Maria Alfaro-Ramirez, Patrick J Kelly, Philip Masson, Rustam Al-Shahi Salman, Angela C Webster

ABSTRACT

Introduction People with end-stage kidney disease (ESKD) have up to 30-fold higher risk of stroke than the general population.

Objective To determine risk factors associated with stroke death in the ESKD population.

Methods We identified all patients with incident ESKD in Australia (1980–2013) and New Zealand (1988–2012) from the Australian and New Zealand Dialysis and Transplant Registry (ANZDATA) registry. We ascertained underlying cause of death from data linkage with national death registries and risk factors from ANZDATA. Using a competing risks multivariable regression model, we estimated cumulative incidence of stroke and non-stroke deaths, and risk factors for stroke deaths (adjusted sub-HR, SHR).

Results We included 60,823 people with ESKD. There were 941 stroke deaths and 33,377 non-stroke deaths during 38,174 person-years of follow-up. Overall, the cumulative incidence of stroke death was 0.9% and non-stroke death was 36.8% 5 years after starting ESKD treatment. The risk of stroke death was higher at older ages (SHR 1.92, 95% CI 1.45 to 2.55), in females (SHR 1.41, 95% CI 1.21 to 1.64), in people with cerebrovascular disease (SHR 2.39, 95% CI 1.99 to 2.87), with ESKD caused by hypertensive/renovascular disease (SHR 1.39, 95% CI 1.09 to 1.78) or polycystic kidney disease (SHR 1.38, 95% CI 1.00 to 1.90), with earlier year of ESKD treatment initiation (SHR 1.93, 95% CI 1.56 to 2.39) and receiving dialysis (transplant vs haemodialysis SHR 0.27, 95% CI 0.09 to 0.84).

Conclusion Patients with ESKD with higher risk of stroke death are older, women, with cerebrovascular disease, with hypertensive/renal or polycystic kidney disease cause of ESKD, with earlier year of ESKD treatment and receiving dialysis. These groups may benefit from targeted stroke prevention interventions.

INTRODUCTION

Compared with the general population, people with end-stage kidney disease (ESKD) have a substantially reduced life expectancy with cardiovascular disease killing more than 50% of people receiving renal replacement therapy (RRT). Globally in developed countries, mortality from cardiovascular diseases has declined since the 1960s, with heart disease deaths declining by 56% in the USA between 1950 and 1996 and all-cause cardiovascular deaths declining by more than 70% in the Netherlands and 60% in the UK and Ireland from 1980 to 2009. Despite people with ESKD having a 5 to 30-fold increased risk of stroke compared with the general population, the epidemiology of stroke death in ESKD is far less clear. An Australian registry-based study reported that for people with ESKD, the relative risk of death from cardiovascular disease between 1992 and 2005 increased compared with the general population, despite absolute cardiovascular death rates falling.

Another contemporary Taiwanese case–control study reported a greater than twofold risk of 30-day mortality following a stroke in people with ESKD compared with propensity-matched controls. Such differences in outcomes between the general population and people with ESKD following a stroke could arise because of...
differences in the prevalence and severity of underlying traditional stroke risk factors including hypertension, diabetes and atrial fibrillation. Stroke case severity may also differ, as might the effectiveness and access to preventative treatments (including aspirin, ACE inhibitors, anticoagulants and statins) and acute stroke interventions including thrombolysis. Risk factors specific to people with ESKD may also exist: accelerated calcific atherosclerosis (from disordered bone metabolism), platelet dysfunction, anaemia. In addition, dialysis-associated osmotic fluid and electrolyte shifts or exposure to glucose degradation products from peritoneal dialysis (PD) fluid may all alter normal pathological glial scar resolution and affect functional outcomes following stroke. For people with kidney transplants, in addition to traditional cardiovascular risk factors, graft function and albuminuria as well as the side effects of immunosuppressive medicines might all modify stroke outcomes.

The aims of our study were to establish robust estimates of stroke and non-stroke death incidence in people with ESKD, and to identify risk factors associated with dying after a stroke.

**METHOD**

**Study design and setting**

We performed a population-based cohort study of all adults and children starting RRT for treatment of ESKD in Australia (1 January 1980 to 31 December 2013) and New Zealand (1 January 1988 to 31 December 2012). Australia (population 24.8 million in 2017) and New Zealand (population 4.7 million in 2017) are broadly comparable in racial make-up and population demographics, where approximately 75% are from a European, Australian or New Zealand cultural background. Both countries have a universal healthcare system that provides free medical care in public health systems. All deaths occurring in each country are reported to the Births, Deaths and Marriages Registry with a medical certificate for the cause of death completed by a medical doctor which is then coded to the international standard, the International Statistical Classification of Diseases and Related Health Problems (ICD), codes by a qualified clinical coder, detailing both the underlying and secondary causes of death. The underlying cause of death is considered as the disease or condition which initiated the sequence of events resulting in death. Secondary or contributing causes of death are other diseases or conditions that contributed to the death but were not the underlying cause.

**Participants, data linkage and death outcomes**

**People with ESKD**

The Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) prospectively collects data from all dialysis and transplant centres in Australia and New Zealand. Data are collected either via web based or printed survey forms in real time as key events occur for each patient with ESKD. Core data collected include demographics (age, sex, country, racial background, body mass index, BMI and smoking history), comorbidities (cerebrovascular disease, diabetes, coronary artery disease, peripheral artery disease and previous malignancy) and modality of treatment for ESKD (type of dialysis or transplant, date initiated and cause of kidney failure). ANZDATA data collection, remit and validation has been previously described elsewhere.

**Data linkage**

We used data linkage of ANZDATA with each of the national death registries in Australia and New Zealand to determine the date and underlying cause of death for people with ESKD. In Australia, patients with ESKD were linked with the National Death Index, which records all deaths from 1980 and is maintained by the Australian Institute of Health and Welfare (AIHW). The Australian Bureau of Statistics (ABS) retrieves information on all deaths and their causes from the Births, Deaths and Marriages Registry in each state and territory. The ABS collates these data and a clinical coder then codes the causes of death to an international standard ICD. The National Centre for Classification in Health has developed an Australian modification version, currently in its Tenth Revision which is referred to as ICD-10-AM. We used probabilistic record linkage for Australian patients with ESKD, matching on date of birth, sex and full name. In New Zealand, patients with ESKD were linked with the Mortality Collection database, which collects information on all deaths from 1988 and is maintained by the New Zealand Ministry of Health. The Ministry receives information from the Births, Deaths and Marriages Registry as well as additional information from medical certif-icates and coroners' reports to classify causes of death into ICD-10-AM. We used deterministic linkage for New Zealand patients with ESKD, matching on the National Health Index number. Hence, our analysis was restricted by the available data in the national death registries. We included all patients with incident ESKD in Australia during 1980–2013 and in New Zealand during 1988–2012.

Data linkage was performed by the AIHW and New Zealand Ministry of Health using best-practice privacy-preserving protocols. After data linkage was complete, only de-identified data were made available for the purposes of this study.

**Death ascertainment, stroke definition and cause of death**

Causes of death were determined using ICD-10-AM diagnosis codes provided in the underlying cause of death from the Australian and New Zealand national death registries. All-cause stroke deaths included subarachnoid haemorrhage (I60.0–I60.9), intracerebral haemorrhages (I61.0–I61.9), intracranial haemorrhages (I62.0–I62.9), ischaemic strokes (I63.0–I63.9), unspecified strokes (I64.0–I64.9) and, transient cerebral ischaemic attacks and related syndromes (G45.0–G45.9). Prior to 1997, the ninth revision of ICD was implemented. There is little evidence for significant differences in stroke coding
between revisions, with agreement being over 90%.\textsuperscript{15,16} All other causes of death were considered as non-stroke deaths.

**Patient and public involvement**

We used retrospective registry data for this study, hence study participants were not involved in the recruitment or design of the study. Patient advisers were also not involved in this study.

**Statistical analyses**

We summarised the main causes of death by deriving the leading causes of death, defined by ICD-10-AM codes.\textsuperscript{17} We also estimated the crude mortality rates for stroke and non-stroke deaths, overall and stratified by patient demographics.

We used Fine and Gray competing risks regression models to evaluate risk factors associated with stroke death.\textsuperscript{18} Time was measured from the start date of ESKD treatment until a participant died or 31 December 2013. For comparison, we also similarly conducted an analysis of non-stroke deaths, with stroke deaths considered as competing events. For both the stroke and non-stroke analyses, we used the same covariates, selected a priori including: age at initiation of ESKD treatment, sex, year of initiating ESKD treatment, country, racial background, BMI category (underweight, ≤18.4 kg/m\(^2\); normal, 18.5–24.9 kg/m\(^2\); overweight, 25.0–29.9 kg/m\(^2\) and obese, ≥30.0 kg/m\(^2\)), initial ESKD treatment modality, comorbidities, smoking status and cause of ESKD. Univariable models were fitted for each covariate, and the multivariable models included all covariates. The cumulative incidence was estimated from the final multivariable model, by sex and year of initiating ESKD treatment, adjusting for all other covariates except BMI.

There were no missing data, except for BMI. Missing values for BMI were imputed using chained equations with five iterations. To impute, we used the same variables as those used in the competing risks analyses, then converted those BMI values into categories for the regression models.

We conducted a further three sensitivity analyses to determine: (1) whether risk factors for any stroke death were similar to risk factors for fatal ischaemic stroke and fatal haemorrhagic stroke; (2) whether risk factors were the same when stroke death was defined as underlying cause, or secondary cause when kidney failure was indicated as the underlying cause and (3) whether ever transplanted with a kidney as a time-varying covariate produced different model estimates. For these sensitivity analyses, we used cause-specific Cox regression models to evaluate associated risk factors and used the same covariates and definition of time at risk as described in the main analysis.

Data were analysed using Stata V.14 (Stata).

**RESULTS**

**Patient characteristics**

We identified a total of 62 296 people with incident ESKD in Australia and New Zealand between 1980 and 2013. Of these, 1473 New Zealand patients initiated RRT prior to 1988 or after 2012, and so could not be linked. The remaining 60 823 patients with ESKD were included in the analysis (figure 1). The fact of death for the majority of patients was similar between ANZDATA and the national death registries, where disagreement occurred for 7.6% of Australian patients and 5.5% of New Zealand patients. There were 467 patients considered to be lost to follow-up in ANZDATA, where 57 patients were considered to have died in the national death registry. There were 381 874 person-years (PYs) of follow-up, with a median follow-up time of 4.0 years (IQR 1.7–8.4 years).

During the study period, 26 505 patients (43%) remained in active follow-up and 34 318 patients (57%) died (table 1). Of the patients who died, 33 377 patients died of non-stroke causes (97.3%) and 941 patients (2.7%) died of stroke. In our entire study population, two-thirds (69%) were aged 50 years or older at ESKD, with a median age of 59 years (IQR 46–69). Most were from Australia (85%), were male (59%), had a Caucasian background (76%) and had started treatment for ESKD.
Table 1 Characteristics of participants with end-stage kidney disease (ESKD), overall and by stroke and non-stroke deaths

| Characteristics | Stroke deaths Total | Non-stroke deaths Total | Total |
|-----------------|---------------------|-------------------------|-------|
|                 | n (%)*              | n (%)*                  | n (%)*|
| Total, (%)      | 941 (2)†            | 33377 (55)†             | 60823 (100) |
| Age at RRT initiation (years) | | | |
| ≤29             | 25 (3)              | 1150 (3)                | 5088 (8) |
| 30–49           | 177 (19)            | 5399 (16)               | 13807 (23) |
| 50–64           | 329 (35)            | 11147 (34)              | 19480 (33) |
| 65–74           | 261 (28)            | 9658 (29)               | 13942 (23) |
| ≥75             | 149 (16)            | 5753 (17)               | 8106 (13) |
| Median (IQR)    | 62 (52–71)          | 63 (53–72)              | 59 (46–69) |
| Sex             |                     |                         | |
| Female          | 472 (50)            | 13901 (42)              | 25042 (41) |
| Male            | 469 (50)            | 19476 (58)              | 35781 (59) |
| Year of ESKD    |                     |                         | |
| ≤1995           | 379 (40)            | 11151 (35)              | 15382 (25) |
| 1996–2005       | 367 (39)            | 14100 (44)              | 22215 (36) |
| 2006–2013       | 195 (21)            | 7162 (21)               | 23326 (38) |
| Country         |                     |                         | |
| Australia       | 819 (87)            | 28173 (84)              | 51451 (85) |
| New Zealand     | 122 (13)            | 5204 (16)               | 9372 (15) |
| Racial background|                    |                         | |
| European        | 737 (78)            | 26286 (79)              | 46025 (76) |
| Indigenous Oceania | 122 (13)        | 5244 (16)               | 9743 (16) |
| Asian           | 78 (8)              | 1667 (5)                | 4357 (7) |
| African and Middle East | 4 (<0.5)         | 154 (<0.5)              | 19 (<0.1) |
| Peoples of the America | 0 (−)          | 4 (<0.1)                | 19 (<0.1) |
| Other‡          | 0 (−)               | 22 (<0.1)               | 187 (<0.4) |
| Body mass index |                     |                         | |
| Underweight (≤18.4) | 32 (3)           | 1274 (4)                | 2702 (4) |
| Normal (18.5–24.9) | 353 (38)         | 10662 (32)              | 19866 (33) |
| Overweight (25.0–29.9) | 209 (22)        | 8670 (26)               | 16641 (27) |
| Obese (≥30)     | 132 (14)            | 6561 (20)               | 13772 (23) |
| Not collected   | 215 (23)            | 6210 (19)               | 7842 (13) |
| Comorbidities at ESKD |              |                         | |
| Cerebrovascular disease | 246 (26)     | 5393 (16)               | 7676 (13) |
| Diabetes        | 313 (33)            | 12863 (39)              | 21717 (36) |
| Coronary artery disease | 372 (40)    | 14310 (43)              | 20785 (34) |
| Peripheral artery disease | 252 (27)    | 9487 (28)               | 13373 (22) |
| Previous malignancy | 208 (22)     | 9707 (29)               | 15788 (26) |
| Smoking status  |                     |                         | |
| Current/former  | 413 (44)            | 16081 (48)              | 28389 (47) |
| Never           | 345 (37)            | 11955 (36)              | 25861 (43) |
| Unknown         | 183 (19)            | 5341 (16)               | 6573 (11) |
| Cause of renal failure |             |                         | |
| Diabetes        | 249 (26)            | 9925 (30)               | 16909 (28) |

Continued
in 1996 or later (74%). The majority of patients had a normal (33%) or overweight (27%) BMI, where only 4% were underweight. The BMI was not collected for 13% of patients, the large majority (95%) of whom reached ESKD prior to 1996. The main cause of ESKD was diabetes (28%), followed by glomerulonephritis/IgA nephropathy (27%), other causes of ESKD (26%), hypertension/renal artery disease (12%) and polycystic kidney disease (7%). The reason for other causes of ESKD included uncertain diagnosis (23%), analgesic nephropathy (18%) and reflux nephropathy (16%).

Deaths
There were a total of 34318 deaths since initiation of ESKD treatment, with a crude rate of 89.9 (95% CI 88.9 to 90.8) per 1000 PYs. The top four leading causes of death were recorded as diabetes (18%), coronary heart disease (18%), kidney failure (13%) and glomerular disease (5%). Stroke was the sixth leading cause of death since RRT, with a total 941 stroke deaths, corresponding to a crude rate of 2.5 (95% CI 2.3 to 2.6) per 1000 PYs (table 2). Stroke deaths were due to: 108 (11%) ischaemic strokes; 259 (28%) intracerebral haemorrhages; 90 (10%) intracranial haemorrhages; 68 (7%) subarachnoid haemorrhages; 114 (12%) transient cerebral ischaemic attacks and related syndromes and 302 (32%) unspecified strokes (online supplementary appendix 1).

The highest rate of stroke death since initiation of ESKD treatment was among those with known cerebrovascular disease at 9.1 (95% CI 8.0 to 10.3) per 1000 PYs, followed by those aged 75 years or older at 6.6 (95% CI 5.6 to 7.7) per 1000 PYs (table 2). In comparison, the highest rate of non-stroke death since initiation of ESKD treatment was among those aged 75 years or older at 254.5 (95% CI 248.0 to 261.2) per 1000 PYs, followed by those with cerebrovascular disease at 199.0 (95% CI 193.7 to 204.4) per 1000 PYs.

Risk factors for stroke mortality
The multivariable model suggested a higher risk of stroke death was associated with older age, female sex, earlier year of ESKD, normal BMI range, presence of pre-existing cerebrovascular disease, no previous malignancy, ESKD treatment with haemodialysis (HD) compared with transplant and hypertension/renal artery disease or polycystic kidney disease as the cause of ESKD compared with glomerulonephritis/IgA nephropathy (table 3).

Older age was associated with a higher risk of stroke death, where patients aged 75 years or older were 92% sub-HR (SHR 1.92, 95% CI 1.45 to 2.55) more likely to die from stroke death compared with those aged 30–49 years (p<0.001). Females were 41% more likely to die of stroke death compared with males (SHR 1.41, 95% CI 1.21 to 1.64; p<0.001). There was a decreasing trend in the risk of stroke death overtime, where patients initiating ESKD treatment in ≤1995 and 1996–2005 were 93% (SHR 1.93, 95% CI 1.56 to 2.39) and 30% (SHR 1.30, 95% CI 1.09 to 1.55), respectively, more likely to die from stroke death compared with those in 2006–2013 (p<0.001). Patients had over two times the increased risk of stroke death if they had pre-existing cerebrovascular disease (SHR 2.39, 95% CI 1.99 to 2.87; p<0.001) and were 36% less likely to die of stroke if they had a previous malignancy (SHR 0.64, 95% CI 0.53 to 0.78; p<0.001). There was no difference in the risk of stroke death for those who initiated PD (SHR 0.85; 95% CI 0.72 to 1.01) compared with HD. However, transplant patients were 73% less likely to die of stroke compared with HD patients (SHR 0.27, 95% CI 0.09 to 0.84). Similar estimates for the risk of stroke death were produced when transplant was considered a time-varying covariate (HR 0.24, 95% CI 0.17 to 0.32; p<0.001) (online supplementary appendix 2). The cause of ESKD was also significantly associated with stroke mortality (p=0.020). Patients with hypertension/renal artery disease or
| Risk Factor                                      | Stroke death | Non-stroke death |
|-------------------------------------------------|--------------|-----------------|
|                                                | Events/person-years | Rate/1000 person-years (95% CI) | Events/person-years | Rate/1000 person-years (95% CI) |
| Overall                                         | 941/381 874    | 2.5 (2.3 to 2.6) | 33 377/381 874 | 87.4 (86.5 to 88.3) |
| Age at study entry (years)                      |              |                 |                |                             |
| ≤29                                             | 25/65 822     | 0.4 (0.3 to 0.6) | 1150/65 822   | 17.5 (16.5 to 18.5) |
| 30–49                                           | 177/125 463   | 1.4 (1.2 to 1.6) | 5399/125 463  | 43.0 (41.9 to 44.2) |
| 50–64                                           | 329/114 712   | 2.9 (2.6 to 3.2) | 11 417/114 712 | 99.5 (97.7 to 101.4) |
| 65–74                                           | 261/53 273    | 4.9 (4.3 to 5.5) | 9658/53 273   | 181.3 (177.7 to 184.9) |
| ≥75                                             | 149/22 604    | 6.6 (5.6 to 7.7) | 5753/22 604   | 254.5 (248.0 to 261.2) |
| Sex                                             |              |                 |                |                             |
| Female                                          | 472/160 000   | 3.0 (2.7 to 3.2) | 13 901/160 000 | 86.9 (85.4 to 88.3) |
| Male                                            | 469/221 874   | 2.1 (1.9 to 2.3) | 19 476/221 874 | 87.8 (86.6 to 89.0) |
| Year of end-stage kidney disease (ESKD)         |              |                 |                |                             |
| ≤1995                                           | 379/164 923   | 2.3 (2.1 to 2.5) | 11 515/164 923 | 69.8 (68.6 to 71.1) |
| 1996–2005                                       | 367/147 631   | 2.5 (2.2 to 2.8) | 14 700/147 631 | 99.6 (98.0 to 101.2) |
| 2006–2013                                       | 195/69 320    | 2.8 (2.4 to 3.2) | 7162/69 320   | 103.3 (101.0 to 105.7) |
| Body mass index category                        |              |                 |                |                             |
| Underweight                                     | 32/21 669     | 1.5 (1.0 to 2.1) | 1274/21 669   | 58.8 (55.7 to 62.1) |
| Normal                                          | 353/128 162   | 2.8 (2.5 to 3.1) | 10 662/128 162 | 83.2 (81.6 to 84.8) |
| Overweight                                      | 209/92 333    | 2.3 (2.0 to 2.6) | 8670/92 333   | 93.9 (91.9 to 95.9) |
| Obese                                           | 132/63 171    | 2.1 (1.8 to 2.5) | 6561/63 171   | 103.9 (101.4 to 106.4) |
| Missing                                         | 215/76 539    | 2.8 (2.5 to 3.2) | 6210/76 539   | 81.1 (79.1 to 83.2) |
| Racial background                               |              |                 |                |                             |
| European                                        | 737/298 450   | 2.5 (2.3 to 2.7) | 26 286/298 450 | 88.1 (87.0 to 89.1) |
| Indigenous Oceania                              | 122/50 614    | 2.4 (2.0 to 2.9) | 5244/50 614   | 103.6 (100.8 to 106.5) |
| Asian                                           | 78/29 196     | 2.7 (2.1 to 3.3) | 1667/29 196   | 57.1 (54.4 to 59.9) |
| Other                                           | 4/3615        | 1.1 (0.4 to 2.9) | 180/3615      | 49.8 (43.0 to 57.6) |
| First dialysis module                           |              |                 |                |                             |
| Haemodialysis                                    | 285/112 334   | 2.5 (2.3 to 2.8) | 10 493/112 334 | 93.4 (91.6 to 95.2) |
| Peritoneal dialysis                              | 652/255 998   | 2.5 (2.4 to 2.8) | 22 735/255 998 | 88.8 (87.7 to 90.0) |
| Transplant                                      | 4/13542       | 0.3 (0.1 to 0.8) | 149/13542     | 11.0 (9.4 to 12.9) |
| Comorbidities at ESKD                           |              |                 |                |                             |
| Cerebrovascular disease                         |              |                 |                |                             |
Table 2  Continued

|                      | Stroke death | Non-stroke death |
|----------------------|--------------|------------------|
|                      | Events/person-years | Rate/1000 person-years (95% CI) | Events/person-years | Rate/1000 person-years (95% CI) |
| **Absent**           | 695/354,770   | 2.0 (1.8 to 2.1) | 27,984/354,770     | 7.89 (7.80 to 7.98) |
| **Present**          | 246/27,104    | 9.1 (8.0 to 10.3) | 5393/27,104        | 199.0 (193.7 to 204.4) |
| **Diabetes**         |              |                  |                  |                          |
| Absent               | 628/291,009   | 2.2 (2.0 to 2.3) | 20,514/291,009     | 70.5 (69.5 to 71.5) |
| Present              | 313/90,865    | 3.4 (3.1 to 3.8) | 12,863/90,865      | 141.6 (139.1 to 144.0) |
| **Coronary artery disease** |      |                  |                  |                          |
| Absent               | 569/3,027,16  | 1.9 (1.7 to 2.0) | 19,067/302,716     | 63.0 (62.1 to 63.9) |
| Present              | 372/79,158    | 4.7 (4.2 to 5.2) | 14,310/79,158      | 180.8 (177.8 to 183.8) |
| **Peripheral artery disease** |   |                  |                  |                          |
| Absent               | 689/333,035   | 2.1 (1.9 to 2.2) | 23,890/333,035     | 71.7 (70.8 to 72.7) |
| Present              | 252/48,839    | 5.2 (4.6 to 5.8) | 9,487/48,839       | 194.3 (190.4 to 198.2) |
| **Previous malignancy** |          |                  |                  |                          |
| Absent               | 733/250,447   | 2.9 (2.7 to 3.1) | 23,670/250,447     | 94.5 (93.3 to 95.7) |
| Present              | 208/131,427   | 1.6 (1.4 to 1.8) | 9,707/131,427      | 73.9 (72.4 to 75.3) |
| **Smoking status**   |              |                  |                  |                          |
| Never/unknown        | 528/230,776   | 2.3 (2.1 to 2.5) | 17,296/230,776     | 74.9 (73.8 to 76.1) |
| Current/former       | 413/151,098   | 2.7 (2.5 to 3.0) | 16,081/151,098     | 106.4 (104.8 to 108.1) |
| **Cause of renal failure** |          |                  |                  |                          |
| Diabetes             | 249/71,417    | 3.5 (3.1 to 3.9) | 9,925/71,417       | 139.0 (136.3 to 141.7) |
| Hypertension/renal artery disease | 169/29,547 | 5.7 (4.9 to 6.7) | 4,763/29,547       | 161.2 (156.7 to 165.8) |
| Glomerulonephritis/IgA nephropathy | 211/140,460 | 1.5 (1.3 to 1.7) | 7,626/140,460      | 54.3 (53.1 to 55.5) |
| Polycystic kidney disease | 71/33,101   | 2.1 (1.7 to 2.7) | 1,623/33,101       | 49.0 (46.7 to 51.5) |
| Other                | 241/107,349   | 2.2 (2.0 to 2.5) | 9,440/107,349      | 87.9 (86.2 to 89.7) |
|                                        | Stroke death | Non-stroke death |
|----------------------------------------|--------------|------------------|
| **Age at study entry (years)**         |              |                  |
| ≤29                                    | 0.43 (0.26 to 0.70) | 0.39 (0.37 to 0.43) |
| 30–49                                  | Ref          | Ref              |
| 50–64                                  | 1.47 (1.16 to 1.86) | 1.96 (1.89 to 2.04) |
| 65–74                                  | 1.82 (1.42 to 2.33) | 3.23 (3.10 to 3.37) |
| ≥75                                    | 1.92 (1.45 to 2.55) | 4.68 (4.45 to 4.91) |
| **Sex**                                |              |                  |
| Male                                   | Ref          | Ref              |
| Female                                 | 1.41 (1.21 to 1.64) | 1.05 (1.02 to 1.08) |
| **Year of ESKD**                       |              |                  |
| ≤1995                                  | 1.93 (1.56 to 2.39) | 1.39 (1.33 to 1.45) |
| 1996–2005                              | 1.30 (1.09 to 1.55) | 1.29 (1.25 to 1.33) |
| 2006–2013                              | Ref          | Ref              |
| **BMI category**                       |              |                  |
| Underweight                            | 0.78 (0.54 to 1.12) | 1.24 (1.16 to 1.33) |
| Normal                                 | Ref          | Ref              |
| Overweight                             | 0.76 (0.64 to 0.90) | 0.93 (0.90 to 0.96) |
| Obese                                  | 0.61 (0.49 to 0.76) | 0.98 (0.95 to 1.02) |
| **Racial background**                  |              |                  |
| Non-white                              | Ref          | Ref              |
| White                                  | 0.88 (0.73 to 1.06) | 1.11 (1.07 to 1.15) |
| **Comorbidities at ESKD**              |              |                  |
| Cerebrovascular disease                |              |                  |
| Present                                | 2.39 (1.99 to 2.87) | 1.13 (1.09 to 1.17) |
| Coronary artery disease                |              |                  |
| Present                                | 1.00 (0.83 to 1.20) | 1.38 (1.34 to 1.42) |
| Peripheral artery disease              |              |                  |
| Present                                | 0.90 (0.74 to 1.09) | 1.30 (1.25 to 1.34) |
| Previous malignancy                    |              |                  |
| Present                                | 0.64 (0.53 to 0.78) | 0.90 (0.88 to 0.93) |
| **Smoking status**                     |              |                  |
| Never/unknown                          | Ref          | Ref              |
| Current/former                         | 1.06 (0.91 to 1.24) | 1.18 (1.15 to 1.21) |
| First dialysis module                  | 0.015        | <0.001           |
| **HD**                                 | Ref          | Ref              |
| PD                                     | 0.85 (0.72 to 1.01) | 1.00 (0.97 to 1.03) |
| Transplant                             | 0.27 (0.09 to 0.84) | 0.26 (0.22 to 0.31) |
| **Cause of renal failure**             |              |                  |
| Diabetes                               | 1.23 (0.99 to 1.54) | 1.60 (1.54 to 1.66) |
| Hypertension/renal artery disease      | 1.39 (1.09 to 1.78) | 1.23 (1.18 to 1.29) |
| Glomerulonephritis/IgA nephropathy     | Ref          | Ref              |
| Polycystic kidney disease              | 1.38 (1.00 to 1.90) | 0.72 (0.68 to 0.76) |

Continued
polycystic kidney disease were 39% (SHR 1.50, 95% CI 1.20 to 1.87) and 38% (SHR 1.38, 95% CI 1.00 to 1.90), respectively, more likely of stroke death compared with those with glomerulonephritis/IgA nephropathy. The unadjusted estimated risk of stroke death is presented in online supplementary appendix 3.

In the sensitivity analysis, the risk of fatal ischaemic stroke was not associated with BMI, cerebrovascular disease, previous malignancy or HD compared with transplant (online supplementary appendix 4). White racial background and coronary artery disease were associated with an increased risk of ischaemic stroke death, which were not risk factors for all-cause stroke death. Year of ESKD was also not associated with the risk of fatal ischaemic or haemorrhagic stroke. The risk factors for fatal haemorrhagic stroke were all similar to the risk factors for all-cause stroke death, except for cause of renal failure (online supplementary appendix 4). Cause of renal failure was not associated with the risk of fatal haemorrhagic stroke.

There were an additional 694 stroke deaths when all-cause stroke death was defined as the underlying cause or secondary cause when kidney failure was the underlying cause. All risk factors associated with the extended definition for all-cause stroke were the same as those identified in the main analysis, except for peripheral artery disease (online supplementary appendix 5). In the sensitivity multivariate model, patients with pre-existing peripheral artery disease were at an increased risk for all-cause stroke mortality.

**Risk factors for non-stroke mortality**

The multivariable model suggested that a higher risk of non-stroke death was associated with older age, female sex, earlier year of ESKD, underweight or normal BMI range, Caucasian background, presence of comorbidities including cerebrovascular disease, coronary artery disease, peripheral artery disease and no previous malignancy, current or former smoker, dialysis compared with transplant and cause of ESKD including diabetes, hypertension/renal artery disease or other causes (table 3). Patients initiating ESKD treatment with a transplant were associated with a 73% lower risk of non-stroke death compared with those initiating HD (SHR 0.27, 95% CI 0.23 to 0.32; p<0.001). Similar estimates for the risk of non-stroke death were produced when transplant was considered a time-varying covariate (HR 0.30, 95% CI 0.29 to 0.32; p<0.001) (online supplementary appendix 2). The cause of ESKD was also significantly associated with non-stroke mortality (p<0.001). A higher risk of non-stroke mortality was associated with diabetes (SHR 1.60, 95% CI 1.54 to 1.65), hypertension/renal artery disease (SHR 1.24, 95% CI 1.19 to 1.29) or other causes (SHR 1.38, 95% CI 1.33 to 1.42) compared with glomerulonephritis/IgA nephropathy as the cause of ESKD. Those with polycystic kidney disease were 24% less likely (SHR 0.76, 95% CI 0.72 to 0.80) to die of non-stroke compared with those with glomerulonephritis/IgA nephropathy. The unadjusted estimated risk of non-stroke death is presented in online supplementary appendix 3.

**Cumulative incidence of death**

The estimated cumulative incidence of stroke mortality since RRT was relatively low at 0.5% at 2years, while the non-stroke mortality was substantially higher at 15.5% at 2years. At 5years, the cumulative incidence increased to 0.9% for stroke and 36.8% for non-stroke mortality.

The cumulative incidence of stroke or non-stroke death differed by sex, where females consistently had a higher cumulative incidence (figure 2A). For stroke mortality, the cumulative incidence at 2years in males was 0.4% and slightly higher in females at 0.6%. At 5years, the sex difference increased where the cumulative incidence was 0.8% in males and 1.1% in females. For non-stroke mortality, the cumulative incidence at 2years was similar in males at 17.6% and females at 17.4%. At 5years, the cumulative incidence remained similar at 43.3% in males and 42.9% in females.

The cumulative incidence of stroke mortality decreased over time, where those diagnosed with ESKD in 2006–2013 had the lowest cumulative incidence during follow-up (figure 2B). At 5years, the cumulative incidence increased to 1.6% in ≤1995, 0.9% in 1996–2005 and 0.7% in 2006–2013. The cumulative incidence of non-stroke mortality showed a similar trend. At 5years, the cumulative incidence increased to 46.3% in ≤1995, 38.0% in 1996–2005 and 30.4% in 2006–2013.

**DISCUSSION**

This multinational study represents the largest study of stroke mortality in people with ESKD to date, including more than 381 000 PPs follow-up in 60 825 people starting treatment for ESKD to evaluate risk factors associated with stroke mortality in the Australia and New Zealand. Our main finding was that women with ESKD were 41%
more likely to die from a stroke death compared with men with ESKD. There was a decreasing trend in stroke mortality risk over time, where patients with incident ESKD in ≤1995 nearly twice as likely to die of stroke death compared those starting ESKD treatment in 2006–2013. We also found that those with cerebrovascular disease were over twofold more likely to die of stroke compared with those without cerebrovascular disease. Other factors associated with an increased stroke mortality risk included older age, normal BMI (vs overweight or obese BMI), no previous malignancy, dialysis treatment compared transplant and hypertension/renal artery disease or diabetes as the cause of ESKD (vs glomerulonephritis/ IgA nephropathy). These risk factors highlight patients with ESKD at greater risk of stroke death that could be targeted in prevention strategies, particularly those with cerebrovascular disease and females.

Our findings suggest a sex difference in stroke mortality where women have at a greater risk of dying following a stroke compared with men. Women have also been shown to have a stroke incidence nearly twice that of men in the Australian ESKD population. This is unlike the Australian and New Zealand general population, where men have a higher stroke incidence but comparable death rate to women. Women may have confounding factors that place them at a greater risk of stroke death. In the general population, women are older at stroke onset, have poorer outcomes after stroke and are more likely to have atrial fibrillation and hypertension. Alternatively, stroke prevention may not be implemented in women as often as men. Previous studies in the general population have found that women were less likely to be prescribed antiplatelet therapy following an ischaemic stroke and less frequently treated with an oral anticoagulant once diagnosed with atrial fibrillation. These gaps in care may also prevail in the ESKD population, however, no studies to date have specifically examined sex differences in stroke prevention among patients with ESKD. Whether a lack of stroke prevention strategies or other factors contribute to female patients with ESKD being at a greater risk of stroke and stroke death still needs further investigation.

Pre-existing cerebrovascular disease presents an opportunity for secondary prevention in the ESKD population, either with existing or novel interventions. Our findings are supported by previous studies of incident and recurrent strokes in the ESKD population. Studies in the UK found that patients with ESKD with prior cerebrovascular disease were 4.5 times more at risk of incident stroke. The mechanisms underlying cerebrovascular disease and ESKD are likely due to a combination of factors. First, CKD and cerebrovascular disease share common risk factors, including older age, diabetes, hypertension, obesity and smoking. Second, CKD-associated risk factors associated with CKD, such as chronic inflammation, oxidative stress and uraemic retention products, contribute to an excess risk of cerebrovascular disease. Third, the dialysis process itself could lead to an increased risk of stroke, such as hyperperfusion in HD and glucose degradation in PD. In transplant patients, graft function and the effect of albuminuria and eGFR may also modify their risk of stroke death. Until now cerebrovascular disease prevention strategies implemented in the ESKD population have mainly been based on stroke interventions in the general population. Secondary stroke prevention can either target modifiable risk factors, such as hypertension and dyslipidaemia, or recommend the use of an anticoagulant or antiplatelet. However, the effectiveness of anticoagulant or antiplatelet therapy in the ESKD population is unclear as patients with ESKD are often under-represented or excluded from prevention trials. The few observational studies in anticoagulation therapy with warfarin suggested little evidence of preventing ischaemic strokes and increased the risk of major bleeding among patients with ESKD undergoing HD. Similarly, there is an absence of trial data on the safety and effectiveness of stroke thrombolysis in people with ESKD. A study examining nephrologist views on stroke thrombolysis showed that most had concerns about the bleeding risks and were uncertain about the overall benefits in patients with ESKD. However, our findings did suggest a decreasing trend in stroke mortality risk over time where those initiating ESKD treatment in recent years were less likely to die of stroke. This may have arisen from improved stroke prevention interventions over time or better renal management. Further
research is still needed to assess whether the effectiveness of secondary stroke prevention could be improved in the ESKD population.

There were similarities and differences in the risk factors associated with stroke and non-stroke mortality. Several risk factors were associated with an increased risk for both stroke and non-stroke death, including older age, earlier year of ESKD, normal BMI compared with overweight BMI, cerebrovascular disease, HD compared with transplant and diabetes or hypertension/renal artery disease compared with glomerulonephritis/IgA nephropathy as cause of renal failure. Female sex was only associated with an increased risk of stroke death. While factors only associated with an increased risk of non-stroke death were underweight BMI compared with normal BMI, white racial background, coronary or peripheral artery disease, current or former smoker and glomerulonephritis/IgA nephropathy compared with polycystic kidney disease as cause of ESKD.

A major strength of our study was our large population-based patient sample that included the entire ESKD population in Australia and New Zealand. We also conducted several sensitivity analyses which were relatively consistent in the risk factors for stroke mortality. This suggests our main analysis was fairly robust and reliable. However, there were several limitations to our study. The limited data collected by ANZDATA did not allow us to evaluate whether secondary stroke prevention interventions were being used in patients with ESKD. In addition, previous studies have shown family history of stroke, blood pressure, atrial fibrillation and laboratory-related data (such as haemoglobin) are strongly associated with mortality in those with cerebrovascular disease and in women as often as men. In addition, implementing prevention strategies in those with prior cerebrovascular disease has the potential to prevent secondary stroke in patients with ESKD. It is unclear whether stroke prevention strategies are as effective in the ESKD population as in the general population. Further research into the use and effectiveness of stroke prevention in the ESKD population is needed to evaluate means of reducing stroke mortality in those with cerebrovascular disease and in females.

Contributors ACW, PM, MA-R and PJK contributed to the concept development. NLDLM, MA-R and PJK contributed to the statistical design. NLDLM and MA-R performed the statistical analysis. NLDLM and PM prepared the draft manuscript. All authors (ACW, PM, MA-R, PJK and RA-SS) contributed to the interpretation of the results, critically revised the manuscript and approved of the final manuscript for submission.

Funding The data reported here have been supplied by the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), the Australian Institute of Health and Welfare (AIHW) and the New Zealand Ministry of Health. We would like to acknowledge the assistance provided by the AIHW and New Zealand Ministry of Health in the data linkage process and Kidney Health Australia for their support. The interpretation and reporting of these data are the responsibility of the Editors and in no way should be seen as an official policy of interpretation of ANZDATA, AIHW or the New Zealand Ministry of Health (Reference No.: 14/NTB/171).

Provenance and peer review This study received ethics approval from the University of Sydney (Project No.: 2014/917), AIHW (Reference No.: E02015/3/181) and the New Zealand Ministry of Health (Reference No.: 14/NTB/171).
properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Collins AJ. Cardiovascular mortality in end-stage renal disease. Am J Med Sci 2003;325:163–7.
2. Schmid H, Schiffl H. Haemodialysis and survival of end-stage renal disease patients: the long journey goes on. Int Urol Nephrol 2012;44:1435–40.
3. Villar E, Chang SH, McDonald SP. Incidences, treatments, outcomes, and sex effect on survival in patients with end-stage renal disease by diabetes status in Australia and New Zealand (1991-2005). Diabetes Care 2007;30:3070–6.
4. Roberts MA, Polkinghorne KR, McDonald SP, et al. Secular trends in cardiovascular mortality rates of patients receiving dialysis compared with the general population. Am J Kidney Dis 2011;58:64–72.
5. Cheng YG, Lin CS, Shih CC, et al. Stroke risk and outcomes in patients with chronic kidney disease or end-stage renal disease: Two nationwide studies. PLoS One 2018;13:e0191155.
6. Keighley DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659–63.
7. Longenecker JC, Coren J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002;13:1918–27.
8. Seliger SL, Glimm DL, Tirschwell D, et al. Risk factors for incident stroke among patients with end-stage renal disease. J Am Soc Nephrol 2003;14:2623–31.
9. Grantham CE, Hull KL, Graham-Brown MPM, et al. The Potential Cardiovascular Benefits of Low-Glucose Degrading Product, Biocompatible Peritoneal Dialysis Fluids: A Review of the Literature. Perit Dial Int 2017;37:375–83.
10. Lentine KL, Rocca Rey LA, Kolli S, et al. Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure. Clin J Am Soc Nephrol 2008;3:1090–101.
11. Australian Bureau of Statistics. General Community Profile. Adelaide, Australia. 2016. http://www.censusdata.abs.gov.au/census_services/getproduct/census/2016/communityprofile/03670endocument (Cited 13 Feb 2018).
12. Statistics New Zealand. New Zealand in Profile 2015: An overview of New Zealand’s people, economy and environment. Wellington, New Zealand, 2015. http://arc档.stats.govt.nz/browse_for_stats snapshots-of-nz-in-profile-2015.aspx. (Cited 13 Feb 2018).
13. McDonald SP, Russ GR. Australian registries-ANZDATA and ANZOD. Transplant Rev 2013;27:46–9.
14. Health, N.C.C.F.C. The International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Australian modification. 9th ed, 2015.
15. Australian Institute of Health and Welfare. Stroke and its management in Australia: an update. Canberra: Australian Institute of Health and Welfare, 2013. https://www.aihw.gov.au/getmedia/3d5d6c949-68a4-46f3-bc7c-c40c89904d8e/15994.pdf.aspx?inline=true. (Cited 23 Apr 2018).
16. Kokota OA, Hill MD. Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke 2005;36:1756–81.
17. Becker R, Silvi J, Ma Fat D, et al. A method for deriving leading causes of death. Bull World Health Organ 2006;84:297–304.
18. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–500.
19. Blakely T, Salmon C. Probabilistic record linkage and a method to calculate the positive predictive value. Int J Epidemiol 2002;31:1246–52.
20. Barker-Collo S, Bennett DA, Krishnamurthi RV, et al. Sex differences in stroke incidence, prevalence, mortality and disability-adjusted life years: Results from the global burden of disease study 2013. Neuroepidemiology 2015;45:203–14.
21. Reeves MJ, Bushnell CD, Howard G, et al. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol 2008;7:915–26.
22. Di Carlo A, Lamassa M, Baldereschi M, et al. Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: data from a multicenter multinational hospital-based registry. Stroke 2003;34:1114–9.
23. Holroyd-Leduc JM, Kapral MK, Austin PC, et al. Sex differences and similarities in the management and outcome of stroke patients. Stroke 2000;31:1833–7.
24. Kapral MK, Fang J, Hill MD, et al. Sex differences in stroke care and outcomes: results from the Registry of the Canadian Stroke Network. Stroke 2005;36:809–14.
25. Roquer J, Campello AR, Gomis M. Sex differences in first-ever acute stroke. Stroke 2003;34:1581–5.
26. Glader EL, Stegmayr B, Norving B, et al. Sex differences in management and outcome after stroke: a Swedish national perspective. Stroke 2003;34:1970–5.
27. Simpson CR, Wilson C, Hannaford PC, et al. Evidence for age and sex differences in the secondary prevention of stroke in Scottish primary care. Stroke 2005;36:1771–5.
28. Findlay MD, Thomson PC, Fulton RL, et al. Risk factors of ischemic stroke and subsequent outcome in patients receiving haemodialysis. Stroke 2015;46:2477–81.
29. Masson P, Kotval S, Kelly PJ, et al. Risk factors for stroke in people with end-stage kidney disease: A cohort study. Cerebrovasc Dis 2016;42(5–6):428–38.
30. Szaiz SM, Armstrong PA, Coresh J, et al. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study. Am J Kidney Dis 2009;54:468–77.
31. Power A, Chan K, Singh SK, et al. Appraising stroke risk in maintenance haemodialysis patients: a large single-center cohort study. Am J Kidney Dis 2012;59:249–57.
32. El Hussein N, Kaskan O, Goldstein LB. Chronic kidney disease and stroke. Adv Chronic Kidney Dis 2014;21:500–8.
33. Harrington W, Haynes R, Staplin N, et al. Evidence for the prevention and treatment of stroke in dialysis patients. Semin Dial 2015;28:35–47.
34. Saeed F, Kousar N, Qureshi K, et al. A review of risk factors for stroke in patients with chronic kidney disease. J Vasc Interv Neurol 2009;2:126–31.
35. Toyoda K, Ninomiya T. Stroke and cerebrovascular diseases in patients with chronic kidney disease. Lancet Neurol 2014;13:823–30.
36. Prohovnik I, Post J, Uribarri J, et al. Cerebrovascular effects of hemodialysis in chronic kidney disease. J Cereb Blood Flow Metab 2007;27:1861–9.
37. Khella S, Bleicher MB. Stroke and its prevention in chronic kidney disease. Clin J Am Soc Nephrol 2007;2:1343–51.
38. Khella SL. New insights into stroke in chronic kidney disease. Adv Chronic Kidney Dis 2008;15:338–46.
39. Townsend RR. Stroke in chronic kidney disease: prevention and management. Clin J Am Soc Nephrol 2008;3 Suppl 1(Suppl 1):S11–S16.
40. Dahal K, Kunwar S, Rijal J, et al. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: A meta-analysis of observational studies. Chest 2016;149:951–9.
41. Winkelmayer WC, Liu J, Setoguchi S, et al. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 2011;6:2662–8.
42. Power A, Fogarty D, Wheeler DC. Acute stroke thrombolysis in end-stage renal disease: a national survey of nephrologist opinion. Nephron Clin Pract 2013;124(3–4):167–72.
43. Centre for Health Record Linkage. Master Linkage Key Quality Assurance. Sydney, Australia, 2012. http://www.cherei.org.au/media/24160/qa_report_2012-a.pdf. (Cited 13 Mar 2018).